Geron Corporation (GERN): Price and Financial Metrics

Geron Corporation (GERN)

Today's Latest Price: $1.69 USD

0.01 (0.60%)

Updated Sep 25 4:00pm

Add GERN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

GERN Stock Summary

  • GERN's price/sales ratio is 1,321.64; that's higher than the P/S ratio of 99.52% of US stocks.
  • With a year-over-year growth in debt of 1,354.48%, Geron Corp's debt growth rate surpasses 98.47% of about US stocks.
  • Revenue growth over the past 12 months for Geron Corp comes in at -43.12%, a number that bests only 4.99% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Geron Corp are CBMG, INO, MRSN, ARNA, and PTN.
  • Visit GERN's SEC page to see the company's official filings. To visit the company's web site, go to
GERN Daily Price Range
GERN 52-Week Price Range

GERN Stock Price Chart Technical Analysis Charts

GERN Price/Volume Stats

Current price $1.69 52-week high $2.40
Prev. close $1.68 52-week low $0.75
Day low $1.67 Volume 2,101,535
Day high $1.72 Avg. volume 2,645,434
50-day MA $1.80 Dividend yield N/A
200-day MA $1.52 Market Cap 524.69M

Geron Corporation (GERN) Company Bio

Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

GERN Latest News Stream

Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream

Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about Geron Corp that investors may wish to consider to help them evaluate GERN as an investment opportunity.

Geron (GERN) Looks Good: Stock Adds 6.5% in Session

Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Yahoo | September 21, 2020

Geron (GERN) Presents At H.C. Wainwright 22nd Annual Global Investment Conference

The following slide deck was published by Geron Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | September 15, 2020

Geron to Present at the H.C. Wainwright Global Investment Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday, September 14, 2020 at 2:30 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, If you

Business Wire | September 9, 2020

How Should Investors Feel About Geron's (NASDAQ:GERN) CEO Remuneration?

Chip Scarlett became the CEO of Geron Corporation (NASDAQ:GERN) in 2011, and we think it's a good time to look at the...

Yahoo | August 24, 2020

Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss second quarter financial results and current events. “In the second quarter, we achieved a number of key milestones that have changed the trajectory of the Company,” said John A. Scarlett, M.D., Chairman and Chief Executive Offi

Business Wire | August 6, 2020

Read More 'GERN' Stories Here

GERN Price Returns

1-mo -12.44%
3-mo -19.52%
6-mo 42.02%
1-year 25.19%
3-year -23.18%
5-year -37.41%
YTD 24.26%
2019 36.00%
2018 -44.44%
2017 -13.04%
2016 -57.23%
2015 48.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8128 seconds.